NURL — Neural Therapeutics Balance Sheet
0.000.00%
- CA$2.66m
- CA$2.41m
Annual balance sheet for Neural Therapeutics, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2022 July 31st | 2023 July 31st | 2024 July 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Cash | |||
Cash and Short Term Investments | 0.372 | 0.273 | 0.067 |
Net Total Receivables | 0.051 | 0.069 | 0.028 |
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 0.455 | 0.351 | 0.096 |
Total Assets | 0.455 | 0.351 | 0.096 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Current Liabilities | 0.464 | 0.473 | 0.306 |
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 0.464 | 0.613 | 0.78 |
Common Stock | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | -0.009 | -0.262 | -0.684 |
Total Liabilities & Shareholders' Equity | 0.455 | 0.351 | 0.096 |
Total Common Shares Outstanding |